Streetwise Reports' Article Archives — June 2022 back to current month (31)
Chen's Top Picks for Q3 (06/30/2022)
Need to know where to go in these turbulent times? Asset manager Chen Lin has some ideas with his top picks for the third quarter.
Shares of BioNTech SE traded 5% higher after the company together with its partner Pfizer Inc. reported that the two firms have agreed to provide 105 million 30 µg, 10 µg and 3 µg new doses of the SARS-Co-V2 vaccine to the U.S. government in a contract valued at $3.2 billion. The agreement includes a provision allowing the U.S. government to purchase up to an additional 195 million doses, which if exercised would increase the grand total to 300 million doses.
New Alzheimer's Drug Shows Promise as Monotherapy (06/29/2022)
Athira Pharma Inc.'s treatment with this small molecule alone resulted in improvements related to both primary and secondary endpoints, indicating pharmacological activity, noted a BTIG report.
Shares of Patterson Companies Inc. traded 11% higher after the dental supply and animal health products distributor reported Q4/22 and FY/22 financial results highlighting a 9.9% increase in annual sales and an expansion in operating margins.
Shares of Sutro Biopharma Inc. traded 21% higher after the company announced it entered into a global collaboration agreement with Japan's Astellas Pharma to advance three novel immunostimulatory antibody-drug conjugates.
In this trial, slated to commence next quarter, the biopharma will test the efficacy of its version of the psychedelic compound in this mental health indication, noted a ROTH Capital Partners report.
The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report.
EU Biopharma Co. Makes $247M Bid for US Oncology Co. (06/27/2022)
Epizyme Inc. shares traded 55% higher today after the company reported that it agreed to be acquired by Ipsen S.A. of France for $1.45 per share along with a contingent value right of $1.00 per share.
Shares of uniQure N.V. traded 26% higher after the company released 12-month treatment data from the low-dose cohort in its Phase 1/2 Huntington's disease clinical trial.
Shares of healthcare technology and services firm Convey Health Solutions Holdings Inc. traded 138% higher after the company reported it received a proposal from majority shareholder TPG Inc. to take the company private. TPG has offered to buy all outstanding shares in Convey that it does not already own for $10.50 per share in cash.
Shares of Biomea Fusion Inc. traded 14% higher after the company reported it dosed the first Multiple Myeloma patient in its Phase 1 COVALENT-101 r/r acute leukemia trial.
Results of Dermatitis Clinical Trial Due This Summer (06/21/2022)
Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report.
Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report.
The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled, noted an H.C. Wainwright & Co. report.
Shares of Global Blood Therapeutics Inc. traded 12% higher after the company reported it has teamed up with New York Jets running back Tevin Coleman and his family to promote education and to offer hope and support to families affected by sickle cell disease.
The arbitration court extended the original deadline for a decision in this case of an alleged breach of contract between TRACON Pharmaceuticals Inc. and I-Mab Biopharma, noted an H.C. Wainwright & Co. report.
Biotech Co. Advances 3 New Clinical Stage Assets (06/16/2022)
Ocugen Inc.'s new diverse product candidates include a COVID vaccine, a gene therapeutic for retinitis pigmentosa, and a cell therapy to prevent osteoarthritis, noted a ROTH Capital Partners report.
These changes earned Reliq Health Technologies Inc. an upgrade in overall rating by independent investment research and advisory firm, Jefferson Research.
Optinose Inc. shares traded 40% higher after the company reported positive top-line data from its Phase 3 ReOpen2 Trial of XHANCE for use in treating chronic sinusitis without nasal polyps.
Biomea Fusion Inc.'s new menin inhibitor is soon to begin clinical human trials after it restored glycemic control and outperformed the standard of care, in animal models.
The response rate to DBV Technologies SA's drug patch in the recent Phase 3 clinical trial was statistically significant, which bodes well for the company as there is currently no approved therapy for children with this condition.
Cogent Biosciences Inc. shares traded 70% higher after the firm reported positive clinical data from Part 1 of its ongoing Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM), a severe hematologic disorder.
Approval would be positive news for Aldeyra Therapeutics Inc. given the market for the indication is large and underserved, noted a BTIG report.
After weathering some major setbacks, PetVivo Holdings Inc. is stepping it up. With their new product for osteoarthritis and the team's perseverance, they may soon show themselves as a diamond in the rough.
Biopharma Co. Meets Primary Endpoints in ARDS Trial (06/08/2022)
MediciNova Inc. shares traded 9% higher after the company released top-line data from its Phase 2 study of MN-166 (ibudilast) in hospitalized COVID-19 patients deemed to be at elevated risk for acute respiratory distress syndrome. In the study, MN-166 demonstrated significant decreases in respiratory failure.
Shares of AeroClean Technologies Inc. traded 150% higher after the company reported it received 510k clearance from the U.S. FDA for its Pūrgo™ medical-grade indoor air purification technology that uses UV-C LEDs to eradicate airborne bacteria, fungi, and viruses, including COVID-19.
Approved Drug Shows Promise in Follicular Lymphoma (06/06/2022)
Comparison of new and previous clinical trial data shows improved efficacy, noted a Wedbush report.
FDA Approval of Drug Could Be on the Way (06/03/2022)
"We continue to see good overall odds of ultimate approval" despite the current delay, noted an H.C. Wainwright & Co. report, regarding Verrica Pharmaceuticals topical drug for molluscum contagiosum, a viral skin infection.
Bristol Myers to Buy Precision Oncology Co. (06/03/2022)
Turning Point Therapeutics Inc. shares traded 116% higher after the company reported it entered into a definitive agreement to be acquired by Bristol Myers Squibb Co. in an all-cash transaction for $76.00 per share.
Precision Oncology Co. Signs $1.325B Licensing Deal (06/02/2022)
Repare Therapeutics Inc. shares traded more than 50% higher after the company reported it entered into a worldwide license and collaboration agreement with Roche AG for its anti-tumor drug camonsertib (RP-3500). The agreement includes an upfront payment of $125 million and up to an additional $1.2 billion in development, sales and royalties if certain milestones are achieved.
The "update should be important for determining EDP-235's potential to tap into this large market," noted a ROTH Capital Partners report.